336 related articles for article (PubMed ID: 36844199)
1. Advances in PET and MRI imaging of tumor hypoxia.
Gouel P; Decazes P; Vera P; Gardin I; Thureau S; Bohn P
Front Med (Lausanne); 2023; 10():1055062. PubMed ID: 36844199
[TBL] [Abstract][Full Text] [Related]
2. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.
Matsumoto K; Szajek L; Krishna MC; Cook JA; Seidel J; Grimes K; Carson J; Sowers AL; English S; Green MV; Bacharach SL; Eckelman WC; Mitchell JB
Int J Oncol; 2007 Apr; 30(4):873-81. PubMed ID: 17332926
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
5. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
6. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
7. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.
Lopci E; Grassi I; Chiti A; Nanni C; Cicoria G; Toschi L; Fonti C; Lodi F; Mattioli S; Fanti S
Am J Nucl Med Mol Imaging; 2014; 4(4):365-84. PubMed ID: 24982822
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
9. Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging.
Colombié M; Gouard S; Frindel M; Vidal A; Chérel M; Kraeber-Bodéré F; Rousseau C; Bourgeois M
Front Med (Lausanne); 2015; 2():58. PubMed ID: 26380261
[TBL] [Abstract][Full Text] [Related]
10. First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer.
Thureau S; Piton N; Gouel P; Modzelewski R; Dujon A; Baste JM; Melki J; Rinieri P; Peillon C; Rastelli O; Lequesne J; Hapdey S; Sabourin JC; Bohn P; Vera P
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439254
[TBL] [Abstract][Full Text] [Related]
11. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
12. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
[TBL] [Abstract][Full Text] [Related]
13. 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction,
Maier FC; Schweifer A; Damaraju VL; Cass CE; Bowden GD; Ehrlichmann W; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Pharmaceuticals (Basel); 2019 Feb; 12(1):. PubMed ID: 30781409
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging.
Bayly SR; King RC; Honess DJ; Barnard PJ; Betts HM; Holland JP; Hueting R; Bonnitcha PD; Dilworth JR; Aigbirhio FI; Christlieb M
J Nucl Med; 2008 Nov; 49(11):1862-8. PubMed ID: 18927340
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
19. Radiolabelled agents for PET imaging of tumor hypoxia.
Kurihara H; Honda N; Kono Y; Arai Y
Curr Med Chem; 2012; 19(20):3282-9. PubMed ID: 22664246
[TBL] [Abstract][Full Text] [Related]
20. Imaging hypoxia and angiogenesis in tumors.
Rajendran JG; Krohn KA
Radiol Clin North Am; 2005 Jan; 43(1):169-87. PubMed ID: 15693655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
